Authors

Latest:

Dr. Rao on Emerging Treatments in HER2+ Metastatic Breast Cancer

Ruta D. Rao, MD, associate professor in the Department of Medicine, Division of Hematology at Rush Medical College, as well as the director of the Coleman Foundation Comprehensive Breast Cancer Clinic and medical director of Rush University Cancer Center, discusses emerging treatments for patients with HER2-positive metastatic breast cancer.

Ruth M. O'Regan, MD

Latest:

Dr O’Regan on Sequencing Considerations in Advanced HR+ Breast Cancer

Ruth O'Regan, MD, discusses considerations for sequencing strategies in advanced hormone receptor–positive breast cancer.

Ruth McCorkle, PhD, FAAN,

Ruth O

Latest:

Dr. O'Regan on Treatment of Breast Cancer in Premenopausal Women

Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses treatment for premenopausal patients with breast cancer.

Ruth O Regan, MD, University of Wisconsin Carbone Cancer Center

Ruth Oâ€™Regan, MD

Latest:

mTOR Biology and the Growing Role for mTOR Inhibitors in the Management of Breast Cancer

The role of mTOR inhibition in breast cancer is evolving, and ongoing studies are evaluating biomarkers that will identify the patients who will benefit.

Ruth O'Regan, MD

Latest:

Dr. O’Regan on the Utility of CDK4/6 Inhibitors in Breast Cancer

Ruth O’Regan, MD, discusses the utility of CDK4/6 inhibitors in breast cancer.

Ruth O'Regan, MD, Grady M

Ruth O’Regan, MD, University of Wisconsin

Ruth ORegan, MD, University of Wisconsin Carbone Cancer Center

Rutika Mehta, MD, MPH

Latest:

Dr. Mehta on Frontline and Adjuvant Treatments in ESCC

Rutika Mehta, MD, MPH, discusses which patients with esophageal squamous cell carcinoma may benefit most from the different frontline treatment options available and highlights key treatment developments with adjuvant immunotherapy plus chemotherapy.

Ryan B. Corcoran, MD, PhD

Latest:

Dr. Corcoran on Targeting HER2 Amplification in CRC

Ryan B. Corcoran, MD, PhD, discusses the presence of HER2 amplification in metastatic colorectal cancer.

Ryan Bookout, PharmD

Latest:

The Sustainability of Rising Drug Prices in Oncology

Ryan Bookout, PharmD, president, Hematology/Oncology Pharmacy Association, clinical pharmacist, Moffitt Cancer Center, discusses the sustainability of the field of oncology as drug prices continue to rise.

Ryan C. Fields, MD

Latest:

ILI Provides Valuable Option for Inoperable Melanoma Metastases

As melanoma becomes more prevalent and more lethal in the United States, a multidisciplinary approach for treating inoperable in-transit metastases has proved to be a viable and valuable option.

Ryan Corcoran, MD, PhD, Massachusetts General Hospital Cancer Center

Ryan D. Cassaday, MD, University of Washington School of Medicine

Ryan D. Gentzler, MD

Latest:

Dr. Gentzler on Combination Therapies in NSCLC

Ryan D. Gentzler, MD, assistant professor, Division of Hematology/Oncology, University of Virginia Health System, discusses combination therapies in non–small cell lung cancer (NSCLC).

Ryan J. Sullivan, MD

Latest:

Dr Sullivan on the Reduction of ctDNA With Tebentafusp in Metastatic Uveal Melanoma

Ryan J. Sullivan, MD, discusses the early reduction of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp and shares how these reductions could correlate with longer overall survival in patients with a best response of stable disease.

Ryan J. Sullivan, MD, Massachusetts General Hospital

Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

Latest:

Advances in the Treatment of Malignant Melanoma